Inactive Instrument

Press Releases RXi Pharmaceuticals Corp Nasdaq

Equities

US74979C8082

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells	Apr. 22	AQ
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)	Apr. 16	AQ
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)	Apr. 11	AQ
National Spotlight Features Phio’s Innovative RNAi Technology Platform	Apr. 03	AQ
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update	Apr. 02	GL
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	Mar. 21	AQ
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research	Mar. 13	AQ
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders	Mar. 06	AQ
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	Jan. 31	AQ
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds	Dec. 07	AQ
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 09	GL
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas	Nov. 09	AQ
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control	Nov. 03	AQ
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)	23-10-12	AQ
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894	23-10-11	AQ
Phio CEO to Speak at Wainwright Conference in New York in September	23-09-06	AQ
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute	23-08-21	AQ
Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update	23-08-10	GL
Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules	23-06-02	PR
Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules	23-05-31	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases RXi Pharmaceuticals Corp Nasdaq

Equities

US74979C8082

Press Releases

Filters